<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384393</url>
  </required_header>
  <id_info>
    <org_study_id>ThisCART19</org_study_id>
    <nct_id>NCT04384393</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ThisCART19 in Patients With Refractory or Relapsed B Cell Malignancies</brief_title>
  <official_title>A Single Dose-escalation Study to Evaluate the Safety and Clinical Activity of Allogeneic Chimeric Antigen Receptor T Cells Targeting CD19 in Patients With Refractory or Relapsed B Cell Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundamenta Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of USTC (Anhui Provincial Hospital)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundamenta Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T&#xD;
      targeting CD19) in patients with refractory or relapsed CD19 positive B cell malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, nonrandomized, open-label study to evaluate the safety and clinical&#xD;
      activity of ThisCART19 in patients with refractory or relapsed CD19 positive B cell&#xD;
      malignancies, such as acute or chronic lymphocytic leukemia, lymphoma and etc. The dose range&#xD;
      is 0.2-60 x 10^6 cells per kg body weight.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2020</start_date>
  <completion_date type="Anticipated">October 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities</measure>
    <time_frame>From infusion to Day 28</time_frame>
    <description>To assess adverse events as dose limiting toxicities as defined by the protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Remission</measure>
    <time_frame>At Day 28 after ThisCART19 infusion</time_frame>
    <description>Proportion of patients in whom with morphologic complete remission (CR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>For Acute Lymphoblastic Leukemia (ALL), Objective response rate(ORR) is the percentage of patients who achieve CR or chronic lymphocytic leukemia(CRi); for chronic lymphocytic leukemia (CLL) and lymphoma, ORR is the incidence of either a complete response (CR) or a partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Duration of Response (DOR) defined as the duration (days) from initial response to disease relapse, progression, or death due to any course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From inclusion up to 1 year</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate of 2 Years</measure>
    <time_frame>At year 2</time_frame>
    <description>The rate of patients whom alive at year 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Related Mortality</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The mortality related with ThisCART19 infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>B Cell Malignancy</condition>
  <arm_group>
    <arm_group_label>ThisCART19 cells injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study, allogeneic anti-CD19 CAR T Cells(ThisCART19 cells) is used to treat patients with refractory or relapsed CD19 positive B cell malignancies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ThisCART19 cells</intervention_name>
    <description>0.2-60 x 10^6 CAR T cells per kg body weight.</description>
    <arm_group_label>ThisCART19 cells injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with relapsed or refractory CD19 positive acute or chronic lymphocytic&#xD;
             leukemia, or lymphoma.&#xD;
&#xD;
          2. No alternative treatment options deemed by investigator.&#xD;
&#xD;
          3. Measurable or detectble disease at time of enrollment.&#xD;
&#xD;
          4. Eastern cooperative oncology group (ECOG) performance status of ≤2.&#xD;
&#xD;
          5. Cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by&#xD;
             an echocardiogram (ECHO).&#xD;
&#xD;
          6. Estimated life expectancy &gt; 12 weeks deemed by investigator.&#xD;
&#xD;
          7. Serum creatinine ≤1.6 mg/dl and/or blood urea nitrogen(BUN) ≤ 1.5 mg/dl .&#xD;
&#xD;
          8. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 5 upper&#xD;
             limit of normal (ULN).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women&#xD;
&#xD;
          2. Uncontrolled infection&#xD;
&#xD;
          3. Active hepatitis B virus or hepatitis C virus infection.&#xD;
&#xD;
          4. Patients who need steroids to control disease.&#xD;
&#xD;
          5. Patients who accepted autologous stem-cell transplantation (ASCT) within 100 days.&#xD;
&#xD;
          6. Patients with grade 2-4 graft-versus-host disease (GVHD), or deemed need to manage by&#xD;
             investigator.&#xD;
&#xD;
          7. History of Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
          8. Patients with active central nervous system (CNS) involvement by malignancy.&#xD;
&#xD;
          9. Patients combine with other disease cause neutrophil count (ANC) &lt; 750 per microlitre&#xD;
             or platelet count (PLT)&lt; 50,000 per microlitre.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingbing Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of USTC (Anhui Provincial Hospital)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Li, Ph.D</last_name>
    <phone>+86-18662604088</phone>
    <email>jli@ctigen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ling He</last_name>
    <phone>+86-18626100886</phone>
    <email>lhe@ctigen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of USTC (Anhui Provincial Hospital)</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingbing Wang</last_name>
      <phone>+86-18056075256</phone>
      <email>wangxingbing@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundamenta Therapeutice Co.,Ltd</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Li</last_name>
      <phone>+8618662604088</phone>
      <email>jli@ctigen.com</email>
    </contact>
    <contact_backup>
      <last_name>Ling He</last_name>
      <phone>+8618626100886</phone>
      <email>lhe@ctigen.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

